



*Scann / w / Lee*

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Dario NERI et al.

Examiner: Alana M. Harris

Serial No.: 09/194,356

Group Art Unit: 1642

Filed: September 2, 1999

Title: ANTIBODIES TO ED-B DOMAIN OF FIBRONECTIN, THEIR CONSTRUCTION  
AND USES

**REPLY**

Mail Stop  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**Advisory Action of February 17, 2006**

The examiner raises two issues allegedly explaining why this application is not in condition for allowance despite the filing of the two Sekiguchi letters.

**First Alleged Reason**

A first letter by Professor Sekiguchi was filed on August 31, 2005. It contains a description of scientific proof establishing that the experiments reported in and disclosure of the two cited Japanese publications (JP H2-76598 and JP H4-169195) do not, in fact, result in the production of antibodies specifically directed to the ED-B domain of fibronectin. This letter did not contain the usual form paragraph for a declaration-type document per MPEP 716.02(g). This problem was solved by the filing of the second Sekiguchi letter on December 28, 2005. The latter specifically referred to the former letter and made all the confirmations and statements required by MPEP 716.02(g) with respect to its contents. Thus, together, these two letters fulfill